Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers discover possible diagnosis, treatment, vaccine for mad cow, prion diseases

02.06.2003


Research led by scientists at the U of T and Caprion Pharmaceuticals have uncovered the basis for a diagnostic, immunotherapy and vaccine, providing a way to detect and treat the brain-wasting damage of infectious prions like those found in mad cow disease and its human version, Creutzfeldt-Jakob Disease.


Microscopic image of a tissue sample from a human brain that shows a clump of infectious prions (dark pink area).
Credit: Dr. Neil Cashman of the University of Toronto.


representation showing the tyrosine-tyrosine-arginine amino acid sequence (the yellow, green and purple clumps) on the infectious prion.
Credit: Dr. Neil Cashman of the University of Toronto.



Dr. Neil Cashman, a principal investigator at U of T’s Centre for Research in Neurodegenerative Diseases and professor in the Department of Medicine (neurology) and a Caprion founder, says a vaccine approach - which would likely be of most use in animals and livestock - could prevent animals from becoming infected. For humans with diseases like classical or variant Creutzfeldt-Jakob, an immunotherapeutic would provide patients with antibodies that bind infectious prions, enabling the immune system to recognize and attack them. For both humans and animals, the diagnostic screening potential of this discovery could significantly improve the safety of the human blood and food systems.

Cashman, who also holds the Jeno Diener Chair in Neurodegenerative Diseases at U of T, says his team tried a new approach in studying infectious prions, which are particles thought to be composed of normal prion proteins that have been compromised and folded into rogue shapes. "The usual way of raising antibodies in the immune system is to grind the infectious agent up and inject it into a mouse to see if it prompts antibody production," he says. "Scientists have tried this method with prions over the past 15 years, all without success. My group decided to examine it from the sub-molecular level to determine if antibodies would recognize and react to the amino acids exposed at the surface of a prion. It was a novel idea, and when we found that our hypothesis actually worked, we were surprised and pleased." The researchers’ findings are reported online in the June 1 version of Nature Medicine.


All mammals have prion proteins, the highest levels of which are present in the brain, explains Cashman, a senior scientist at Sunnybrook and Women’s Research Institute and a neurologist in the Department of Medicine at Sunnybrook and Women’s College Health Sciences Centre. Mammals can contract prion diseases by ingesting abnormal or infectious prions. From the digestive system, these prions make their way to the brain. When an abnormal prion comes in contact with a normal prion protein, it causes the protein to misfold, thus creating a copy of the infectious prion. Cashman says the process is more akin to co-opting than replication. However, since the abnormal prion has similar characteristics to the original host protein, the immune system does not recognize it as a foreign invader and does not attack it.

In their study, Cashman and his colleagues examined the role of chemical groups in amino acids, which are called side chains. "We wanted to see whether there were side chains accessible on abnormal prions that were not accessible on the normal protein. We hypothesized that in a normal prion protein, there will be side chains buried in the interior of the molecule. When the protein converts to the abnormal form, we thought that some of these side chains would then be exposed on the molecular surface. We discovered that the newly exposed side chains of abnormal prions include a sequence composed of three amino acids - tyrosine, tyrosine and arginine (Tyr-Tyr-Arg). By raising antibodies against the Tyr-Tyr-Arg amino acid sequence, the immune system became able to recognize the abnormal prion as an invader and attack it."

"It was a ’Eureka!’ moment," he recalls. "Significantly, while the antibodies recognized the abnormal prions, they left the normal prion proteins intact."

Cashman and his team further found that the tyrosine-tyrosine-arginine amino acid sequence appears to be common among species. "Different species have different sequences of prion proteins," he says. "But this Tyr-Tyr-Arg motif appears to be the same in every species that we’ve been able to look at - humans, cattle, mice, hamsters, sheep and elk. When we applied our antibodies to the infected tissues and cells of our samples, they only bound to the abnormal prion protein in all these species."

The researchers are currently testing a possible vaccine to prion disease in mice. They plan to immunize mice with the Tyr-Tyr-Arg sequence and then infect them with prions.

"In order to treat prion diseases in the most effective way possible, it is necessary to understand the manner in which prion proteins fold into a pathological form," says Dr. Bhagirath Singh, scientific director of the Institute of Infection and Immunity of the Canadian Institutes of Health Research. "Dr. Cashman’s discovery is a vital step in understanding the causes of prion diseases and will play key a role in developing vaccines and a new generation of drugs to combat this condition."

The immediate commercial applications of the discoveries are diagnostics, as global health authorities urgently seek to ensure that beef and transfused blood are safe from Mad Cow-related infections. "Neil’s discovery represents the single most promising hope for diagnosing and treating this fatal disease," notes Lloyd M. Segal, president and CEO of Caprion. Caprion has already announced collaborations with Johnson & Johnson and IDEXX Laboratories to apply these technologies for the development of diagnostics for prion-related diseases, he adds.


Caprion provided the major funding and support for this pioneering research and own all commercial applications of the discoveries. This research was also supported by the Canadian Institutes of Health Research and McDonald’s Corp.

CONTACT:

Janet Wong
U of T Public Affairs
416-978-5949
jf.wong@utoronto.ca

Neil Cashman
Centre for Research in Neurodegenerative Diseases
416-978-1875
neil.cashman@utoronto.ca

Kathie Darlington
Caprion Pharmaceuticals Inc.
514-940-3608


Janet Wong | EurekAlert!
Further information:
http://www.caprion.com
http://www.utoronto.ca/

More articles from Agricultural and Forestry Science:

nachricht Back to Nature: Palm oil plantations are being turned back into protected rainforest
21.03.2019 | Forschungsverbund Berlin e.V.

nachricht The inner struggle of the evening primrose: Chloroplasts are caught up in an evolutionary arms race
14.03.2019 | Max-Planck-Institut für Molekulare Pflanzenphysiologie

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Energy-saving new LED phosphor

The human eye is particularly sensitive to green, but less sensitive to blue and red. Chemists led by Hubert Huppertz at the University of Innsbruck have now developed a new red phosphor whose light is well perceived by the eye. This increases the light yield of white LEDs by around one sixth, which can significantly improve the energy efficiency of lighting systems.

Light emitting diodes or LEDs are only able to produce light of a certain colour. However, white light can be created using different colour mixing processes.

Im Focus: Quantum gas turns supersolid

Researchers led by Francesca Ferlaino from the University of Innsbruck and the Austrian Academy of Sciences report in Physical Review X on the observation of supersolid behavior in dipolar quantum gases of erbium and dysprosium. In the dysprosium gas these properties are unprecedentedly long-lived. This sets the stage for future investigations into the nature of this exotic phase of matter.

Supersolidity is a paradoxical state where the matter is both crystallized and superfluid. Predicted 50 years ago, such a counter-intuitive phase, featuring...

Im Focus: Explosion on Jupiter-sized star 10 times more powerful than ever seen on our sun

A stellar flare 10 times more powerful than anything seen on our sun has burst from an ultracool star almost the same size as Jupiter

  • Coolest and smallest star to produce a superflare found
  • Star is a tenth of the radius of our Sun
  • Researchers led by University of Warwick could only see...

Im Focus: Quantum simulation more stable than expected

A localization phenomenon boosts the accuracy of solving quantum many-body problems with quantum computers which are otherwise challenging for conventional computers. This brings such digital quantum simulation within reach on quantum devices available today.

Quantum computers promise to solve certain computational problems exponentially faster than any classical machine. “A particularly promising application is the...

Im Focus: Largest, fastest array of microscopic 'traffic cops' for optical communications

The technology could revolutionize how information travels through data centers and artificial intelligence networks

Engineers at the University of California, Berkeley have built a new photonic switch that can control the direction of light passing through optical fibers...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

Fraunhofer FHR at the IEEE Radar Conference 2019 in Boston, USA

09.04.2019 | Event News

 
Latest News

Proteins stand up to nerve cell regression

24.04.2019 | Life Sciences

New sensor detects rare metals used in smartphones

24.04.2019 | Life Sciences

Controlling instabilities gives closer look at chemistry from hypersonic vehicles

24.04.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>